Abstract
To clarify drug therapies and actual use of oral hypoglycemic agents (OHA) and insulin preparations (INS) in patients with type 2 diabetes mellitus in Japan, we analyzed clinical data collected from 41 institutes using CoDiC®, an electronic system for diabetes data collection and management. Cross-sectional surveys were made of 14,246, 17,576, and 19,228 type 2 diabetic patients registered in 2002, 2003, and 2004. Monotherapy with OHA was done in 38% of patients, combination therapy with OHAs in 32%, combination therapy with INS plus OHA in 10%, and monotherapy with INS in 20%. Among patients receiving OHA, sulfonylureas (SU) were mostly prescribed, but biguanides (BG) and other OHAs are become increasingly used. BG was mostly combined with SU in patients treated with combination therapy of OHAs. α-glucosidase inhibitors (α-GI), BG, and SU were mostly used in patients receiving combination therapy of INS plus OHA. In patients receiving monotherapy with INS, the use of premixed types of insulin have decreased and regular insulin or rapid-acting human insulin analog plus NPH insulin or long-acting human insulin analog therapy have increased.
